By Indication

Spasticity & Neurolytic Indications Market Analysis

Cross-industry research covering Spasticity & Neurolytic Indications across 1 market reportspanning Pharmaceuticals / Medical Devices — Regional Anesthesia.

1 Reports
1 Industries

Reports Covering Spasticity & Neurolytic Indications

Nerve Blocks Market to Reach USD 9.4 Billion by 2033 at 6.4% CAGR

Pharmaceuticals / Medical Devices — Regional Anesthesia·Market: USD 5.7 Billion (2025)·CAGR: 6.4%

Chemical neurolysis with phenol for spasticity management in stroke sequelae and spinal cord injury, combined with botulinum toxin (nct:NCT07440173), represents a small but clinically differentiated indication. Reimbursement pathways differ from surgical block coding; neurolytic procedures are typically covered under distinct CPT codes (64600–64640 series) with separate facility and professional fee structures. Payer coverage policy for repeat neurolytic procedures varies materially across commercial and Medicaid plans.

6%

Market Share

5.3%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments